Journal
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume 16, Issue 6, Pages 457-461Publisher
ADIS INT LTD
DOI: 10.1007/s40257-015-0156-2
Keywords
-
Categories
Funding
- Bayer
- Galderma
Ask authors/readers for more resources
Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews new treatment options including ivermectin, brimonidine, the new foam formulation of azelaic acid, and oxymetazoline. The potential role in therapy, patient selection, and adverse effects of these agents are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available